Accéder au contenu
Merck

Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice.

Neuroscience letters (2014-11-30)
Craige C Wrenn, Andrew M Heitzer, Alexandra K Roth, Lauren Nawrocki, Maria G Valdovinos
RÉSUMÉ

Fragile X syndrome (FXS), a disorder caused by a mutation in the FMR1 gene, is often associated with Attention Deficit Hyperactivity Disorder (ADHD). Common treatments for the hyperactivity often seen in ADHD involve the use of stimulants and α2-adrenergic agonists. The Fmr1 knockout (KO) mouse has been found to be a valid model for FXS both biologically and behaviorally. Of particular interest to our research, the Fmr1 KO mouse has been demonstrated to show increased locomotion in comparison to wild type (WT) littermates. In the present study, we assessed the effects of clonidine (0.05 mg/kg) and methylphenidate (5 mg/kg) on motor activity in Fmr1 KO mice and their WT littermates in the open field test. Results showed that methylphenidate increased motor activity in both genotypes. Clonidine decreased motor activity in both genotypes, but the effect was delayed in the Fmr1 KO mice.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Clonidine hydrochloride, solid
Sigma-Aldrich
Methylphenidate hydrochloride
Supelco
Benzoylecgonine-d3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Benzoylecgonine-d3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Clonidine hydrochloride, European Pharmacopoeia (EP) Reference Standard